Crossroads Automotive Group Inc. is a privately-held automotive dealership group based in Sanford, North Carolina, founded in 1996. The company specializes in new and used vehicle sales, service, and collision repair, operating multiple locations across North Carolina and Virginia. With a workforce of approximately 1,345 employees, Crossroads Automotive Group generates annual revenue of about $232 million. The company is committed to a customer-centric vehicle buying experience, guided by Christian principles. It emphasizes hiring skilled staff, maintaining large inventories, and providing compassionate service. Crossroads Automotive Group has expanded through acquisitions, including brands like Ford, Lincoln, INFINITI, Chrysler, Dodge, Jeep, and Ram. In addition to vehicle sales, the company offers automotive service, collision repair, maintenance, and financing options. It operates under various names, including Crossroads Ford and Crossroads Auto Group, and has established a strong presence in the automotive market.
Blue Jay Racing is a student-run design team open to all undergraduate students. The program was founded in 2004. The team competes annually in three international events put on by the Society of Automotive Engineers. Students design, build, and race a single seat off-road vehicle against a total of ~200 teams representing 14 nations and nearly 4,000 young engineers. The award-winning program offers student engineers an educational experience that goes beyond what the classroom can offer. Aside from the technical knowledge gained, the team-based skills learned through such a rigorous endeavor develops leaders well prepared to enter industry and academia. At each competition the team competes in four of six dynamic events (Acceleration, Maneuverability, Rock Crawl, Suspension and Traction, Hill Climb and Sled Pull) as well as three static events (a sales presentation, design presentations and a cost report). To cap off the competition, the team will also race in a grueling four-hour endurance race. Team members learn as much at competition as from designing and building their vehicle throughout the rest of the year. In addition to their own learning it is also important to the team that all members participate. At competition the team is always working, whether repairing their vehicle or planning and preparing for the next days events. With so much to do and so little time every member contributes to the teams success.
Northstar Power LLC is the solution expert when it comes to your diesel and component part needs. Our common sense approach in the application of John Deere, Kohler and Yanmar® Diesel Engines, Funk Hydraulic Power Train Products, Transfluid Fluid Couplings, and Rubber Track products is no more than an E-mail or phone call away. Whether its a new application or a question regarding an existing application, we have the staff with a wealth of experience and the necessary resources to present you with common-sense solutions to your needs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.